Security key
68232V884
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW)
CUSIP: 68232V884
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, par value $0.01 per share
- Shares outstanding
- 16,062,541
- Total 13F shares
- 1,732,309
- Share change
- +557,029
- Total reported value
- $3,984,315
- Price per share
- $2.30
- Number of holders
- 18
- Value change
- +$1,207,345
- Number of buys
- 10
- Number of sells
- 7
Report period
Q1 2025
Institutions
18
Top holders
10
TRAW full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68232V884
Recent filing periods:
Top shareholders of TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. |
13F
13D/G
|
Company |
9.9%
from 13D/G
|
116,714
|
$1,036,420 | — | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.8%
|
605,531
|
$5,377,115 | — | 31 Dec 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1%
|
164,157
|
$1,457,714 | — | 31 Dec 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.61%
|
98,493
|
$874,618 | — | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.47%
|
75,000
|
$666,000 | — | 31 Dec 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
28,431
|
$108,177 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.13%
|
20,801
|
$184,727 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.1%
|
15,725
|
$139,638 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.08%
|
13,141
|
$116,693 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.06%
|
10,052
|
$89,262 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.06%
|
10,012
|
$88,907 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.06%
|
9,956
|
$88,409 | — | 31 Dec 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
1,164
|
$10,336 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
791
|
$7,024 | — | 31 Dec 2024 | |
| Vermillion & White Wealth Management Group, LLC |
13F
|
Company |
0%
|
205
|
$1,820 | — | 31 Dec 2024 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
155
|
$1,376 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
76
|
$675 | — | 31 Dec 2024 | |
| Pacific Capital Wealth Advisors, Inc. |
13F
|
Company |
0%
|
2
|
$18 | — | 31 Dec 2024 | |
| Viriom, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,645,100
|
$1,480,590 | — | 03 Apr 2024 | |
| Steven M. Fruchtman |
3/4/5
|
PRESIDENT, CHIEF EXECUTIVE OFF, Director |
—
mixed-class rows
|
121,014
mixed-class rows
|
$98,282 | — | 13 Mar 2024 | |
| Abraham N. Oler |
3/4/5
|
SVP Corp Dev & Gen Counsel |
—
mixed-class rows
|
96,197
mixed-class rows
|
$36,818 | — | 07 Feb 2022 | |
| Mark Patrick Guerin |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
44,755
mixed-class rows
|
$23,400 | — | 05 Feb 2025 | |
| Mark S. Gelder MD |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
82,667
mixed-class rows
|
$13,847 | — | 13 Mar 2023 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
—
class O/S missing
|
1
|
$7 | — | 31 Dec 2024 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
164,000
|
— | — | 16 Sep 2024 | |
| Victor M. Moyo |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
125,000
|
— | — | 02 Oct 2023 | |
| James J. Marino |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Jerome Groopman |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Peter Atadja |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Viren Mehta |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 |
Institutional Holders of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) as of Q1 2025
As of 31 Mar 2025,
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,732,309 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, BOOTHBAY FUND MANAGEMENT, LLC, Ikarian Capital, LLC, UBS Group AG, and VANGUARD GROUP INC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
17
Q1 2025 holders
18
Holder diff
1
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.